The ALDH1B1 Knockout NCI-H1703 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1703 human lung adenocarcinoma epithelial cell line. This product introduces a targeted disruption of the ALDH1B1 gene, creating a heterogeneous pool of edited cells for loss-of-function studies. Unlike clonal cell lines, the polyclonal format retains diverse genetic backgrounds, enabling robust assessment of gene function while minimizing potential clonal artifacts. The knockout model is suitable for investigating ALDH1B1-dependent phenotypes without requiring single-cell isolation.
NCI-H1703 is a tumorigenic cell line originally isolated from the pleural effusion of a 54-year-old male smoker with lung adenocarcinoma. It carries a point mutation in TP53 (p.R273H), which inactivates the tumor suppressor protein p53, while KRAS and EGFR genes remain wild-type. This genetic background provides a clinically relevant model for studying lung adenocarcinoma biology, particularly in the context of p53 deficiency. The cells exhibit epithelial morphology and are widely used in cancer research to explore oncogenic signaling, drug responses, and metastatic properties.
ALDH1B1 encodes a mitochondrial aldehyde dehydrogenase that plays a critical role in detoxifying reactive aldehydes. It catalyzes the oxidation of acetaldehyde to acetate during ethanol metabolism and converts lipid peroxidation-derived 4-hydroxynonenal (4-HNE) into less toxic species, thereby mitigating oxidative stress. ALDH1B1 activity generates retinoic acid, a signaling molecule that activates nuclear retinoic acid receptors (RARs) and influences cellular differentiation and stem cell maintenance. Its expression is upregulated by transcription factors such as NF-??B, AP-1, NRF2, and HIF-1??, and can be induced by ethanol exposure. ALDH1B1 functionally interacts with alcohol dehydrogenase, cytochrome P450 2E1, and ALDH2, and may form heterodimers with ALDH1A1, coupling multiple metabolic and signaling networks.
In NCI-H1703 cells, ALDH1B1 is implicated in promoting cancer stem cell characteristics and chemoresistance, partly through enhanced aldehyde clearance and retinoic acid signaling. The p.R273H TP53 mutation disrupts p53-mediated apoptosis and cell cycle regulation, creating a permissive environment for aldehyde-induced DNA damage if detoxification is compromised. By disrupting ALDH1B1 in this background, researchers can dissect its contribution to tumorigenicity, resistance to platinum-based chemotherapies, and survival under oxidative stress. This model is particularly valuable for studying how aldehyde metabolism intersects with p53-dependent pathways in lung adenocarcinoma.
This polyclonal knockout pool enables a range of functional assays to characterize ALDH1B1’s role. Western blotting and RT-qPCR confirm gene disruption; the Aldefluor assay measures ALDH enzymatic activity; MTT viability assays under acetaldehyde stress assess metabolic detoxification capacity; colony and sphere formation assays evaluate stemness and self-renewal; RNA-seq reveals transcriptomic changes; retinoic acid quantification links pathway output; and drug sensitivity screening identifies chemoresistance mechanisms. Applications include alcohol-related cancer studies, lung adenocarcinoma stem cell analysis, aldehyde toxicity profiling, and identification of targetable vulnerabilities in p53-mutant tumors. For additional technical information and ordering support, please contact Ascent Research.
